Anixa Biosciences (NASDAQ:ANIX) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Anixa Biosciences (NASDAQ:ANIX) from a "hold" to a "sell"; the stock's analyst mix is three Buys, one Hold and one Sell, with a consensus rating of "Hold" and a $9.00 consensus price target.
• ANIX opened at $2.83 with a market cap of about $94.9 million, is loss-making (negative P/E) and analysts project roughly -$0.41 EPS for the current year; the 1‑year trading range is $2.33–$5.46.
• Director Arnold M. Baskies purchased 10,000 shares at $3.04, increasing his stake to 135,000 shares (insiders own 26.4%), while hedge funds and other institutions hold about 29.13% of the stock.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Sunday.

Several other research analysts also recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Zacks Research cut Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 18th. Finally, D. Boral Capital reissued a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $9.00.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.83 on Friday. The stock has a market capitalization of $94.89 million, a P/E ratio of -8.58 and a beta of 0.48. Anixa Biosciences has a 1 year low of $2.33 and a 1 year high of $5.46. The company's fifty day moving average is $3.03 and its two-hundred day moving average is $3.55.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. Sell-side analysts predict that Anixa Biosciences will post -0.41 EPS for the current year.

Insider Transactions at Anixa Biosciences

In other news, Director Arnold M. Baskies bought 10,000 shares of the business's stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, with a total value of $30,400.00. Following the transaction, the director owned 135,000 shares of the company's stock, valued at $410,400. This represents a 8.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 26.40% of the company's stock.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. Marshall Wace LLP purchased a new stake in Anixa Biosciences in the 2nd quarter worth about $39,000. NewEdge Advisors LLC purchased a new position in Anixa Biosciences during the 2nd quarter valued at about $33,000. Jane Street Group LLC increased its holdings in shares of Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock valued at $138,000 after purchasing an additional 11,340 shares during the period. Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at about $37,000. Finally, World Investment Advisors purchased a new stake in shares of Anixa Biosciences in the third quarter worth approximately $48,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.